Form 4: Apogee CMO Exercises Options, Sells Shares

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and subsequently sold common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), reported transactions on November 5, 2025.
• Exercised options to acquire 8,060 shares of common stock at an exercise price of $22.86 per share.
• Sold a total of 10,785 shares of common stock in multiple transactions at weighted average prices ranging from $53.62 to $56.51.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.
• Following these transactions, Carl Dambkowski directly beneficially owns 282,008 shares of common stock.
• Remaining derivative holdings include stock options to purchase 153,565 shares, which vest in monthly installments through December 18, 2027.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving an option exercise and subsequent sale under a pre-arranged 10b5-1 plan. While the officer is realizing gains, which is positive for the individual, the transaction itself is generally considered neutral for the company's stock price as it was pre-planned and not indicative of new information.

Positives

• The exercise of options and subsequent sale indicate that the company's stock price has appreciated significantly above the option exercise price, allowing the officer to realize substantial gains.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned sales rather than a reaction to immediate company news, which can mitigate negative interpretations of insider selling.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the officer's direct equity stake in the company.

Risks

• No specific company operational or financial risks are disclosed in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports a routine insider transaction (option exercise and sale under a 10b5-1 plan) and does not provide information to analyze broader industry trends or competitor activities. Such transactions are common across industries for executives managing their equity compensation.

Comparison to Industry Standards

• This filing is a standard insider transaction report and does not contain information suitable for comparison to global benchmarks, specific comparable companies, projects, or results.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale by a Chief Medical Officer, even under a 10b5-1 plan, might lead to minor short-term sentiment shifts, but the pre-planned nature typically limits significant impact. The realization of gains by an executive can be seen as a positive sign of past stock performance.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continued vesting of the remaining 153,565 stock options in forty-eight equal monthly installments through December 18, 2027, subject to Carl Dambkowski's continued service to Apogee Therapeutics.

Key Dates

Keywords

Apogee Therapeutics, APGE, Carl Dambkowski, Chief Medical Officer, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Equity Compensation